REDWOOD CITY, Calif., Sept 21 /PRNewswire/ -- Emphasys Medical Inc., announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its common stock. All of the shares in the proposed offering will be sold by Emphasys.
The underwriters of the offering will be Morgan Stanley & Co. Incorporated as sole book runner and Thomas Weisel Partners LLC, Leerink Swann LLC., and Canaccord Adams Inc. as co-managers. The number of shares to be offered and the price range for the offering have not yet been determined.
The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus relating to the offering may be obtained from Morgan Stanley & Co. Incorporated by emailing email@example.com, or by contacting the prospectus department at Morgan Stanley & Co. Incorporated, 180 Varick, New York, NY 10014, telephone (866) 718-1649.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. This registration statement is available on the Securities and Exchange Commission website at http://edgar.sec.gov. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About Emphasys Medical
Emphasys Medical is a privately held medical technology company focused on developing and commercializing therapeutic devices for the treatment of patients with emphysema and other debilitating breathing disorders. Emphasys recently completed a pivotal clinical trial to demonstrate the efficacy and safety of its first product, the Emphasys Bronchial Valve, in patients with emphysema. Emphasys submitted its application for pre-market approval to the U.S. Food and Drug Administration in September 2007.
Emphasys Medical Inc.
CONTACT: Mark Murray, CFO of Emphasys Medical Inc., +1-650-216-0160,firstname.lastname@example.org; or Nicole Foderaro of WeissComm Partners,+1-415-946-1058, email@example.com, for Emphasys Medical Inc.